Scientific Data Presentations
Explore Thryv Therapeutics’ scientific presentations spanning our research programs in Long QT Syndrome, heart failure, atrial fibrillation, and fibrosis.
Long QT Syndrome (LQTS) Scientific Presentations
SGK-1 INHIBITION WITH LQT-1213 SIGNIFICANTLY REDUCES THE QTCF IN PATIENTS WITH CONGENITAL LONG QT SYNDROME IN THE WAVE I, PART 2 STUDY
Heart Rhythm Society Annual Meeting — San Diego, CA | April 2025
SGK1 INHIBITION SHORTENS ACTION POTENTIAL DURATION IN LQT3 MICE AND LQT2 RABBITS VIA INHIBITION OF LATE SODIUM CURRENT
American Heart Association Scientific Sessions — Chicago, IL | November 2024
ATTENUATION OF DRUG-INDUCED QT-PROLONGATION IN GUINEA PIG ISOLATED HEART AND ANESTHETIZED DOG MODELS OF DRUG-INDUCED QT PROLONGATION BY SERUM/GLUCOCORTICOID REGULATED KINASE 1 (SGK-1) INHIBITORS
Heart Rhythm Society Conference — Boston, MA | May 2024
SGK-1 INHIBITOR ATTENUATES QTCF PROLONGATION IN A DOFETILIDE-INDUCED HUMAN MODEL (WAVE I CLINICAL STUDY)
American College of Cardiology Conference — Atlanta, GA | March 2024
SGK1 INHIBITION ATTENUATED THE ACTION POTENTIAL DURATION IN PATIENT- AND GENOTYPE-SPECIFIC RE-ENGINEERED HEART CELLS WITH CONGENITAL LONG QT SYNDROME
American Heart Association Scientific Sessions — Chicago, IL | November 2022
SGK1 INHIBITION AND ATTENUATION OF ACTION POTENTIAL DURATION IN RE-ENGINEERED HEART CELL MODELS OF DRUG-INDUCED QT PROLONGATION
American Heart Association Scientific Sessions — Chicago, IL | November 2022
Heart Failure (HF) Scientific Presentations
SMALL MOLECULE INHIBITORS OF SERUM GLUCOCORTICOID KINASE 1 (SGK1) PREVENT CARDIAC STRUCTURAL AND FUNCTIONAL DECLINE IN A TRANSVERSE AORTIC CONSTRICTION (TAC) MODEL
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THRV-1268, A POTENT AND SELECTIVE SERUM AND GLUCOCORTICOID REGULATED KINASE (SGK1) INHIBITOR, IMPROVES ADVERSE CARDIAC REMODELING BETTER THAN JARDIANCE® (EMPAGLIFLOZIN), A SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR IN HEART FAILURE
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THE SERUM AND GLUCOCORTICOID REGULATED KINASE 1 (SGK1) INHIBITOR THRV-1268 ATTENUATES HALLMARKS OF HEART FAILURE BY REDUCING INFLAMMATION AND FIBROSIS BEYOND SODIUM/GLUCOSE COTRANSPORTER 2 INHIBITION
American Heart Association Scientific Sessions — New Orleans, LA | November 2025
THRV-1268, A NOVEL AND POTENT SGK1 INHIBITOR, IMPROVED ADVERSE CARDIAC REMODELING BEYOND EMPAGLIFLOZIN, AN SGLT2 INHIBITOR, BY REDUCING INFLAMMATION AND FIBROSIS MECHANISMS IN HEART FAILURE
European Society of Cardiology (ESC) Congress — Madrid, Spain | August 2025
SERUM GLUCOCORTICOID REGULATED KINASE 1 (SGK-1) INHIBITOR REDUCED HYPERTENSION IN A SALT-SENSITIVE HYPERTENSION MODEL OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
American Heart Association Scientific Sessions — Chicago, IL | November 2024
SGK1 INHIBITION ATTENUATED LEFT VENTRICULAR THICKENING AND DIASTOLIC DYSFUNCTION IN A MOUSE MODEL OF HFPEF
American Heart Association Scientific Sessions — Chicago, IL | November 2024
Atrial Fibrillation (AF) Scientific Presentations
A NOVEL SGK1 INHIBITOR (SGK1-I) PREVENTS OBESITY-RELATED ATRIAL FIBRILLATION
American Heart Association Scientific Sessions — Philadelphia, PA | November 2023
Fibrosis Scientific Presentations
SERUM AND GLUCOCORTICOID REGULATED KINASE 1 (SGK1) INHIBITION INDUCES ANTI-FIBROTIC AND ANTI-INFLAMMATORY RESPONSES: RELEVANCE TO CARDIAC FIBROSIS
American Heart Association Scientific Sessions — Chicago, IL | November 2024